Abstract:
This invention seeks to provide methods and apparatus for analysis. Electromagnetic radiation is transmitted through a plurality of metallic islands on a transparent substrate. A resultant optical property of the plurality of metallic islands is measured. Thereafter a chemical substance is adsorbed onto the plurality of metallic islands so as to produce a chemical substance-metallic islands moiety. Electromagnetic radiation is transmitted through the chemical substance-metallic islands moiety and a resultant optical property of metallic islands in the chemical substance-metallic islands moiety is measured. The resultant optical property of the metallic islands in chemical substance-metallic islands moiety and the resultant optical property of the plurality of metallic islands are employed so as to provide at least one of a quantitative indication and a qualitative indication of at least one of: the chemical substance-metallic islands moiety, a functionality of the chemical substance-metallic islands moiety, the plurality of metallic islands, a functionality of the plurality of metallic islands, the chemical substance and a functionality of the chemical substance.
Abstract:
Antibodies to tumor necrosis factor receptors (TNF-Rs) are disclosed together with methods of producing them. The antibodies are preferably those which inhibit the cytotoxic effect of TNF but not its binding to the TNF-Rs. Most preferably, the antibodies bind to an extracellular domain of the C-terminal cysteine loop of the p75 TNF receptor, which loop consists of the amino acid sequence Cys-185 to Thr-201 of SEQ ID NO:3.
Abstract translation:公开了肿瘤坏死因子受体(TNF-Rs)的抗体及其生产方法。 抗体优选是抑制TNF的细胞毒作用但不与TNF-R结合的抗体。 最优选地,抗体结合p75 TNF受体的C-末端半胱氨酸环的细胞外结构域,该环由SEQ ID NO:3的氨基酸序列Cys-185至Thr-201组成。
Abstract:
Proteins capable of modulating the function of FAS/APO1 are provided. The proteins may be prepared by culturing a host cell transformed with a vector containing the DNA encoding such a protein under suitable conditions and isolating the protein.
Abstract:
The present invention is directed towards degumming a silk fiber, obtaining high quality silk fibroin solutions and the reconstitution of silk. The invention further relates to a method of accurately and precisely determining mechanical properties of biological fibers such as silk fibers.
Abstract:
Using a pre-trained and fixed Vision Transformer (ViT) model as an external semantic prior, a generator is trained given only a single structure/appearance image pair as input. Given two input images, a source structure image and a target appearance image, a new image is generated by the generator in which the structure of the source image is preserved, while the visual appearance of the target image is transferred in a semantically aware manner, so that objects in the structure image are “painted” with the visual appearance of semantically related objects in the appearance image. A self-supervised, pre-trained ViT model, such as a DINO-VIT model, is leveraged as an external semantic prior, allowing for training of the generator only on a single input image pair, without any additional information (e.g., segmentation/correspondences), and without adversarial training. The method may generate high quality results in high resolution (e.g., HD).
Abstract:
A method of analyzing the likelihood of weight regain in a subject who has reached a target weight by practicing a weight loss program is disclosed. The method comprises determining an amount or presence of at least one microbe and/or product thereof in the gut microbiome of the subject, wherein the amount of the at least one microbe is altered during a prior weight gain period of the subject to reach a level representative of an obese subject and further wherein the amount of the at least one microbe is retained at the level following the weight loss program, wherein the amount or presence of the at least one microbe or product thereof is predictive of weight regain.
Abstract:
A method of treating a malignant disease involving T cell exhaustion in a subject, with the proviso that said malignant disease is not a B cell malignancy, is disclosed. The method comprising administering to the subject a therapeutically effective amount of an agent capable of decreasing an activity or expression of CD84, thereby treating the malignant disease involving the T cell exhaustion. Also disclosed is a method of treating an autoimmune or inflammatory disease in a subject, the method comprising administering to a subject a therapeutically effective amount of an agent capable of decreasing an activity or expression of CD84. A method comprising administering to the subject a therapeutically effective amount of an agent capable of decreasing an activity or expression of SLAMF1, with the proviso that said agent is not an agent capable of decreasing an activity or expression of CD84, is also disclosed.
Abstract:
This invention is directed to a catalytic hydrogenation process for the preparation of 1-(4-(benzyloxy)-3-(hydroxymethyl)phenyl)-2-(tert-butylamino)ethanol, which is an intermediate for the preparation of Salbutamol.
Abstract:
A multispecific antibody is provided. The antibody comprises a first antigen binding moiety, which specifically binds to an immune checkpoint protein on intratumor T cells and a second antigen binding moiety which specifically binds to a conventional dendritic cell 1 (cDC1). Also provided are uses of such antibodies in cancer treatment.